Company Filing History:
Years Active: 1985-1989
Title: The Innovations of Andrew J Crame
Introduction
Andrew J Crame is a notable inventor based in Greenford, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds with selective adrenoreceptor antagonist action. With a total of 2 patents to his name, Crame's work has the potential to impact various medical treatments.
Latest Patents
Crame's latest patents include innovative compounds that have shown promise in treating a range of health conditions. One of his patents focuses on heterocyclic amino compounds, which are characterized by their selective α₂-adrenoreceptor antagonist action. These compounds can be synthesized through the amination of specific precursors, offering a pathway for new therapeutic options. Another patent involves benzodioxinopyrrole derivatives, which are also designed to act as selective α₂-adrenoreceptor antagonists. These compounds are indicated for the treatment or prevention of conditions such as migraine, diabetes, obesity, and depression, showcasing their potential in modern medicine.
Career Highlights
Crame is currently associated with Glaxo Group Limited, a leading company in the pharmaceutical industry. His work at Glaxo has allowed him to focus on the development of innovative compounds that address significant health challenges. His contributions to the field have been recognized through his patents, which reflect his expertise and commitment to advancing medical science.
Collaborations
Crame has collaborated with notable colleagues, including Alan D Borthwick and John Kitchin. These partnerships have likely enhanced the research and development process, leading to the successful creation of his patented compounds.
Conclusion
Andrew J Crame's work exemplifies the spirit of innovation in the pharmaceutical industry. His patents not only highlight his inventive capabilities but also promise advancements in the treatment of various medical conditions. His contributions continue to shape the future of healthcare.